Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179,578 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial.
He Z, Yang X, Ma T, Yang Q, Zhang C, Chen Y, Wang P, D'Incecco A, Metro G, Uematsu S, Wang Q. He Z, et al. Among authors: chen y. Transl Lung Cancer Res. 2022 Aug;11(8):1657-1666. doi: 10.21037/tlcr-22-558. Transl Lung Cancer Res. 2022. PMID: 36090635 Free PMC article.
Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial.
He Z, Zhou H, Wang J, Li D, Zhang X, Wang P, Ma T, Zhang Y, Tian C, Chen Y, Zou M, Han Y, Xu C, Ma S, Wang L, Wu X, Chen G, Wang Q. He Z, et al. Among authors: chen g, chen y. Transl Lung Cancer Res. 2021 Feb;10(2):889-899. doi: 10.21037/tlcr-20-1235. Transl Lung Cancer Res. 2021. PMID: 33718030 Free PMC article.
179,578 results
You have reached the last available page of results. Please see the User Guide for more information.